Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail.
Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail.
复制标题
监狱中使用药物治疗阿片类药物使用障碍的相关性和模式。
DOI：
10.1097/adm.0000000000001180
复制
发表时间：
2023
影响因子：
5.5
通讯作者：
Evans,ElizabethA
中科院分区：
文献类型：
--
作者：
Bailey,Amelia;Senthilkumar,Rithika;Evans,ElizabethA
目的：监狱中阿片类药物使用障碍（MOUD，即丁丙诺啡、美沙酮、纳洛酮）治疗的相关性知之甚少。我们评估了全国第一监狱提供的2个MOUD计划的实施和结果，以提供获得此类Career.MethodsWe检查了使用MOUD的成人阿片类药物使用障碍（n= 347）监禁在马萨诸塞州的2个农村监狱（2018-2021）。我们研究了MOUD从摄入到监禁期间的转变。使用Logistic回归，我们研究了相关因素在监狱使用MOUD.ResultsAt入狱，48.7%的阿片类药物使用障碍的个人正在接受治疗MOUD。在监禁期间，65.1%的人接受MOUD，这归因于美沙酮使用增加了9.2%（从15.9%增加到25.1%），丁丙诺啡使用增加了10.1%（从28.5%增加到38.6%）。在监禁期间，32.3%的人继续在同一个MOUD从社区，25.4%开始，8.9%停止，7.5%转换类型。总共有25.9%的人进入监狱时没有使用任何MOUD，也没有开始使用MOUD。在监禁期间使用MOUD与在社区中接受MOUD呈正相关（比值比，12.2; 95%置信区间，5.8-25.5）和在研究中心1与研究中心2相比的嵌顿（OR，24.6; 95%CI，10.9-54.4）.ConclusionsExpanded access to MOUD in jails can engage a risk population with treatment.了解与这一人群使用MOUD相关的因素可能有助于在监禁期间和重返社区后优化护理。
ObjectivesLittle is known about the correlates of use of medications to treat opioid use disorder (MOUD, ie, buprenorphine, methadone, naltrexone) offered in jails. We evaluated the implementation and outcomes of a MOUD program offered by 2 of the first jails nationwide to provide access to such care.MethodsWe examined use of MOUD among adults with opioid use disorder (n= 347) incarcerated by 2 rural jails in Massachusetts (2018–2021). We examined MOUD transitions from intake to during incarceration. Using logistic regression, we examined factors associated with in-jail use of MOUD.ResultsAt jail entry, 48.7% of individuals with opioid use disorder were being treated with MOUD. During incarceration, 65.1% received MOUD, attributable to a 9.2% increase in use of methadone (from 15.9% to 25.1%) and a 10.1% increase in use of buprenorphine (from 28.5% to 38.6%). During incarceration, 32.3% of individuals were continued on the same MOUD from the community, 25.4% were started, 8.9% stopped, and 7.5% switched type. A total of 25.9% entered jail not on any MOUD and were not started on it. Use of MOUD during incarceration was positively associated with having received MOUD in the community (odds ratio, 12.2; 95% confidence interval, 5.8–25.5) and incarceration at site 1 compared with site 2 (OR, 24.6; 95% CI, 10.9–54.4).ConclusionsExpanded access to MOUD in jails can engage an at-risk population with treatment. Understanding factors related to this population’s use of MOUD may aid efforts to optimize care during incarceration and after community re-entry.